Suzhou Siyuan

Suzhou Siyuan Biopharma is a clinical-stage biotechnology company headquartered in the Suzhou Industrial Park, China, focused on developing innovative small molecule drugs for oncology and inflammatory diseases. The company's primary focus is on targeting transcriptional regulation and cell cycle control mechanisms to treat refractory cancers. Its lead asset, SY-001, is a highly selective, orally bioavailable CDK7 inhibitor currently undergoing Phase 1 clinical trials for advanced solid tumors. Founded by industry veterans with extensive experience in global pharmaceutical R&D, Siyuan Biopharma aims to build a robust pipeline of first-in-class or best-in-class therapeutics through its proprietary drug discovery platform. The company is supported by leading venture capital firms and is part of the vibrant BioBAY biotechnology cluster.